



## **REGENXBIO to Participate in Upcoming Investor Conferences**

November 8, 2021 12:00 PM EST

ROCKVILLE, Md., Nov. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences, which will each be held in a virtual meeting format:

### **Barclays Gene Editing & Gene Therapy Summit**

Presentation: Monday, November 15, 2021, at 1:30 p.m. ET

### **Piper Sandler 33rd Annual Virtual Healthcare Conference**

Date: December 2, 2021

Recorded Fireside Chat will be available: Monday, November 22, 2021, at 10:00 a.m. ET

A live webcast of the Barclays presentation and the recording of the Piper Sandler fireside chat can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com) for approximately 30 days following the events.

### **About REGENXBIO Inc.**

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

REGENXBIO's NAV<sup>®</sup> Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

### **Contacts:**

Tricia Truehart  
Investor Relations and Corporate Communications  
347-926-7709  
[ttruehart@regenxbio.com](mailto:ttruehart@regenxbio.com)

Investors:  
Brendan Burns, 212-600-1902  
[brendan@argotpartners.com](mailto:brendan@argotpartners.com)

Media:  
David Rosen, 212-600-1902  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301418127.html>

SOURCE REGENXBIO Inc.